Middle East Tech Today
SEE OTHER BRANDS

The best science and technology news from the Middle East

Middle East Tech Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East Tech Today.

Press releases published on April 29, 2025

Olon Group, 프랑스 법인 통해 두 명의 전략적 임원 선임으로 바이오 생산 분야 리더십 강화에 나서

Olon Group, 프랑스 법인 통해 두 명의 전략적 임원 선임으로 바이오 생산 분야 리더십 강화에 나서

밀라노, April 29, 2025 (GLOBE NEWSWIRE) -- 글로벌 제약 CDMO (위탁개발생산) 기업인 Olon Group이 프랑스 법인의 CEO로 Jérôme Bédier를, 생물학적 제제 CDMO 서비스 전담 사업부인 Olon Biotech의 M…

Olon Group Memperkukuh Kepimpinannya dalam Bioproduksi dengan Dua Pelantikan Strategik di Perancis

Olon Group Memperkukuh Kepimpinannya dalam Bioproduksi dengan Dua Pelantikan Strategik di Perancis

MILAN, April 29, 2025 (GLOBE NEWSWIRE) -- Olon Group, sebuah CDMO farmaseutikal global terkemuka, mengumumkan pelantikan Jérôme Bédier sebagai Ketua Pegawai Eksekutif bagi entiti di Perancis dan Andrea Conforto sebagai Naib Presiden M…

Olon Group 在法国完成两项战略性任命,进一步巩固其在生物生产领域的领先地位

Olon Group 在法国完成两项战略性任命,进一步巩固其在生物生产领域的领先地位

米兰, April 29, 2025 (GLOBE NEWSWIRE) -- 全球领先的制药合同研发生产组织 (CDMO) Olon Group 宣布任命 Jérôme Bédier 为其法国子公司的首席执行官,同时任命 Andrea Conforto 担任旗下专注于生物制剂 CDMO 服务的业务部门——Olon Biotech CDMO 事业部的市场和销售副总裁。 上述任命进一步巩固了 Olon 在抗体药物偶联物 (ADC)、高活性原料药 (HPAPI) 及微生物生物生产领域拓展能力的战略布局。 ADC、 …

Olon Group 在法國的兩項戰略任命加強了其在生物製藥領域的領導地位

Olon Group 在法國的兩項戰略任命加強了其在生物製藥領域的領導地位

米蘭, April 29, 2025 (GLOBE NEWSWIRE) -- 全球領先的藥物合同訂製研發和生產組織 (CDMO) 公司 Olon Group 宣布任命 Jérôme Bédier 為其法國實體的行政總裁,並任命 Andrea Conforto 為 Olon 生物技術部門的 CDMO 市場及銷售副總裁 (M…

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene …

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall …

Atsena Therapeutics to Present at May Scientific Conferences

Atsena Therapeutics to Present at May Scientific Conferences

DURHAM, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced it will present at the following …

Repligen Reports First Quarter 2025 Financial Results

Repligen Reports First Quarter 2025 Financial Results

Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growth Orders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic …

ZenaTech’s ZenaDrone Subsidiary Will Showcase its Drones to US Defense Potential Customers at Major Upcoming Conferences

ZenaTech’s ZenaDrone Subsidiary Will Showcase its Drones to US Defense Potential Customers at Major Upcoming Conferences

VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and …

DATE CORRECTION – Amerigo will report Q1-2025 Financial Results on May 7, 2025

DATE CORRECTION – Amerigo will report Q1-2025 Financial Results on May 7, 2025

VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is issuing the following date correction, which was included in its Operational Results news release issued on …

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $590 - $605 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on …

Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter …

Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)

Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)

twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system twiist with Eversense 365 launch expected in Q3 MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- …

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has …

Oxford-Harrington Rare Disease Centre Appoints Majid Jafar to its Advisory Council

Oxford-Harrington Rare Disease Centre Appoints Majid Jafar to its Advisory Council

Mr. Jafar is a distinguished international business leader and co-founder of the Loulou Foundation OXFORD, UK and CLEVELAND, Ohio, US, 29 April 2025 – The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and …

Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race Paris, April 29, 2025. Sanofi is proud to unveil an exciting new chapter in its mission to fight meningitis, as it …

Communiqué de presse :

Communiqué de presse :

Quand chaque seconde compte : Sanofi, McLaren Racing et United Autosports s'unissent pour sensibiliser à la méningite aux 24 Heures du Mans Paris, le 29 avril 2025. Sanofi est fière de présenter une nouvelle étape significative dans sa mission de lutte …

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial …

Dianthus Therapeutics to Participate in Two Upcoming Investor Events

Dianthus Therapeutics to Participate in Two Upcoming Investor Events

NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune …

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

MENLO PARK, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service